Join us for a webinar exploring the revolutionary way SAAmplify™–αSYN testing, which is offered by Mayo Clinic Laboratories in collaboration with Amprion, is improving diagnostic accuracy for patients with neurodegenerative disorders.

Review five crucial patient safety practices that everyone can utilize to promote patient safety.

Early and accurate detection of heparin-induced thrombocytopenia (HIT) and thrombotic thrombocytopenic purpura (TTP) is critical to improving patient outcomes. The following podcast episodes feature expert[...]

Performed on cerebrospinal fluid, Mayo Clinic’s RT-QuIC prion test can distinguish prion disease from other types of rapidly progressive dementias to enhance patient care.

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories. They discuss recent business trends in diagnostics and why it is important for pathologists to stay informed about these trends.

In this episode of Mayo Clinic Laboratories’ “Leveraging the Laboratory” podcast, host Jane Hermansen, outreach manager at Mayo Clinic Laboratories, is joined by colleagues Ellen Dijkman Dulkes and Brianne Newton. They discuss and share tips related to gathering customer input.

Mayo Clinic Laboratories’ guidance for subtyping influenza A in response to a CDC advisory for hospitalized patients

This month's episode of Lab Medicine Rounds, Justin Kreuter, M.D. speaks with Monica Ibarra, M.S., about the essential role of diversity, equity, and inclusion in healthcare and beyond.

PACE/State of FL - This webinar will discuss the advantages of using electrophysiology results to guide the selection of axonal or demyelinating testing for peripheral neuropathy. This approach can help identify specific antibodies associated with the condition, providing a more precise diagnosis, and improving patient outcomes. Accurate diagnosis is crucial for effective treatment, as the therapeutic approach varies based on the underlying cause of peripheral neuropathy.

Sanjeev Sethi, M.D., Ph.D., explains how Mayo Clinic Laboratories' new mass spectrometry test (Mayo ID: MSMN) identifies most antigens now known to cause membranous nephropathy. Precise identification of antigens is important for optimal management of this serious kidney disease.

Surveys are crucial for strengthening laboratory operations. Get insights for how to make them as effective as possible.

This microlearning will help learners develop the ability to include autoimmune movement disorders and related phenomena as part of the differential diagnosis, gain proficiency in categorizing autoimmune movement disorders based on phenotype and clinical progression, and identify effective strategies for diagnosing and managing autoimmune movement disorders.

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories. They discuss Dr. Morice’s recent article in Becker’s Hospital Review, “Nine Developments Predicted to Shape Laboratory Medicine and Diagnostics in 2025.

The healthcare and diagnostics landscape is poised for transformative changes driven by technological advancements and evolving market dynamics.

Justin Fugelsang and Zach Pedowitz have never met. Yet both young men were diagnosed with a rare form of Charcot-Marie-Tooth disease, called sorbitol dehydrogenase (SORD) deficiency, and both found clarity through Mayo Clinic Laboratories' innovative SORD testing. Their journeys inspire resilience, as Justin has channeled his emotions into guitar playing, and Zach has embraced educational leadership.